Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Ocugen Falls After FDA Declines EUA for Covaxin

Published 03/04/2022, 10:16 AM
Updated 03/04/2022, 10:18 AM
© Reuters.

By Sam Boughedda

Investing.com -- Ocugen, Inc. (NASDAQ:OCGN) dropped Friday after it announced the FDA declined to issue Emergency Use Authorization (EUA) approval for Covaxin, Covid-19 vaccine for use in individuals aged 2 to 18 years.

The clinical-stage biopharmaceutical company's shares — which once traded around the $600 mark — fell over 23% on the news Friday.

Covaxin is developed by Ocugen's partner in India, Bharat Biotech. The two companies entered a deal in late 2020 under which Ocugen would develop, supply, and commercialize Covaxin for the US market.

Last week, Ocugen surged after news the FDA lifted its clinical hold for Covaxin. However, that rise was short-lived.

Ocugen said it intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.

Latest comments

Why should we hold on to your shares? Are there any developments in pipeline?
Is there any other product this company is intending to work on? Or is if gonna go to 0?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.